Dyne wins new Outperform at BMO

Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at BMO Capital Markets
Stock analysts at BMO Capital Markets started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $50.
Dyne Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Kostas Biliouris initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm
BMO Capital Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation
Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Dyne Therapeutics (NasdaqGS:DYN) with a Outperform recommendation. As of March 4, 2025, the average one-year price target ...
Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a report issued on Friday,Benzinga reports. They currently have a $50.00 target price on the stock.
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating
BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of $12.
Dyne wins new Outperform at BMO on prospects for lead drug
Dyne Therapeutics (DYN) stock gains premarket momentum as BMO Capital Markets issus a new Outperform rating on the company. Read more here.
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 ...
Yahoo Finance15d
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?
When Might Dyne Therapeutics Run Out Of Money? A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Dyne Therapeutics last reported its December 2024 balance ...